The decision is based on positive results from the Phase III CASPIAN trial, in which the drug increased overall survival. More: FDA grants Imfinzi Priority Review Source: News
read moreHowever, Brexit and competition from countries like USA, Germany and Japan are cited as reasons the UK can’t seem to hold its competitive edge globally. More: UK head of Europe for early clinical research Source: News
read moreThe anti-TNF drug works by targeting a protein in the body called TNF-alpha. More: Celltrion bags EU approval for Remsima SC off back of new data Source: News
read moreThe impressive achievements in pharmaceutical marketing excellence were recognised last night at PMLiVE’s annual PMEAs at the Royal Lancaster London Hotel, with the exciting introduction of a new award for 2019. More: PMEA 2019 winners announced Source: News
read moreThe information makes it “impossible to see how the original target for 5,000 extra GPs could be met by 2020”. More: NHS workforce report shows ‘precarious’ positioning of organisation Source: News
read moreThe boom is thanks in part to a change in the funding landscape, expressed in a four-fold increase to £2.8 billion of investment in early-stage ventures. More: New report shows ‘baby boom’ in life science ventures Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals